

RECEIVED
CENTRAL FAX CENTER

MAY 22 2007

CROMPTON | SEAGER | TUFTE | LLC

Patent, Trademark & Copyright Attorneys

1221 Nicollet Avenue, Suite 800
Minneapolis, Minnesota 55403-2420
Phone 612.677.9050
Fax 612.359.9349**FAX TRANSMISSION**

DATE: May 22, 2007

TO: Commissioner for Patents
Mail Stop M Correspondence
P.O. Box 1450
Alexandria, VA 22313-1450

FROM: Glenn M. Seager

OUR REF.: 1001.2029101
TELEPHONE: 612.359.9312

Total pages, including cover letter: 5

PTO FAX NUMBER 571-273-8300

If you do NOT receive all of the pages, please telephone us at 612.677.9050 or fax us at 612.359.9349.


Title of Document Transmitted:

**Revocation of Power of Attorney with New
Power of Attorney and Change of
Correspondence Address; Authorization
Statement; Statement Under 37 CFR 3.73(b);
and Fee Address Change**

Applicant:	Thomas J. Hiblar et al.	
Serial No./Patent No:	09/829,486	04/09/01
Filed/Issued:	6,800,083	10/05/04
Our Ref. No.:	1001.2029101	
Customer No.:	28075	

By: /glenn m. seager/
Glenn M. Seager, Reg. No. 36,926

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on the date shown below.


JoAnn LindmanMay 22, 2007
Date

PTO/SB/02 (01-08)

Approved for use through 12/31/2008 OMB 0851-0035
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**REVOCATION OF POWER OF
ATTORNEY WITH
NEW POWER OF ATTORNEY
AND
CHANGE OF CORRESPONDENCE ADDRESS**

Application Number	09/829,486
Filing Date	04/09/01
First Named Inventor	Thomas J. Hibler
Art Unit	NA
Examiner Name	NA
Attorney Docket Number	1001 2028101

RECEIVED
CENTRAL FAX CENTER
MAY 22 2007

I hereby revoke all previous powers of attorney given in the above-identified application.

☐ A Power of Attorney is submitted herewith.

OR

☒ I hereby appoint the practitioners associated with the Customer Number.

28075

☒ Please change the correspondence address for the above-identified application to:

☒ The address associated with
Customer Number

28075

OR

☐ Firm or
Individual Name

Address

City

State

Zip

Country

Telephone

Email

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Signature

Name

Todd Messall, Patent Attorney for Boston Scientific Scimed, Inc.

Date

May 10, 2007

Telephone

763-494-1700

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☐ Total of _____ forms are submitted.

This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**LIMITED AUTHORIZATION TO ACT ON BEHALF OF ASSIGNEE
REGARDING CERTAIN PATENT MATTERS
EFFECTIVE THROUGH: December 31, 2007**


I, Paul W. Sandman, as Executive Vice President, Secretary, and General Counsel of Boston Scientific Corporation, the controlling corporation of:

A-Med Systems, Inc.; Advanced Bionics Corporation, Advanced Stent Technologies, Inc.; Afx, Inc.; AMS Medinvent S.A.; BEI Medical Systems; BEI Medical Systems Operating Company (formerly known as Xylog Corporation); BEI Medical Systems International, Inc.; Boston Scientific BV; Boston Scientific Corporation Northwest Technology Center, Inc.; Boston Scientific Ireland Limited; Boston Scientific Japan KK; Boston Scientific Limited, Boston Scientific Scimed, Inc. (formerly known as Schneider (USA), Inc.); Boston Scientific Scimed, Inc. (formerly known as Scimed Life Systems, Inc.); Cardiac Pacemakers, Inc.; Cardiac Pathways Corporation, Cardiothoracic Systems, Inc.; Cardiovascular Innovations Canada, Inc.; Catheter Innovations Corp.; Corvita Canada, Inc.; Corvita Corporation; Corvita Europe S.A.; CryoVascular Systems, Inc.; Embolic Protection, Inc.; Embrio Vascular, LLC; Enable Medical Corporation; EndoTex Interventional Systems, Inc.; Endovascular Technologies, Inc. (EVT); Enteric Medical Technologies, Inc.; EP Technologies, Inc.; Fidus Medical Technology Corporation; Guidant Corporation, Guidant Holdings, Inc.; Guidant Intercontinental Corporation, Guidant Investment Corporation, Guidant Puerto Rico Sales Corporation; Guidant Sales Corporation; Heart Technologies; Inflow Dynamics Inc.; Intermedics, Inc.; Interventional Technologies, Inc.; Laboratoires Corvita S.A.R.L.; Meadox Medicals, Inc.; NAMIC Eireann Limited; NAMIC International, Inc.; Nilo Holding, S.A.; Origin Medsystems, Inc.; Precision Vascular Systems, Inc.; Prohold Medical Corporation; Prohold Technologies, Inc.; Provaxis Therapeutics, Inc.; Quantum Corporation; Radio Therapeutics Corporation; Rubicon Medical Corporation; Rubicon Medical, Inc.; Schneider (Europe) GmbH; Schneider Belgium NV; Schneider Holland BV; Schneider Ireland BV; Schneider Puerto Rico (formerly known as NAMIC Caribe, Inc.); Schneider/NAMIC, Scimed Life Systems, Inc.; Smart Therapeutics, Inc.; Sub-Q, Inc.; Symbiosis Corporation; Target Therapeutics, Inc.; TriVascular, Inc.; and Vesica;

hereby authorize the following registered patent attorneys/agents (1) to act on behalf of any of the corporations identified above, including Boston Scientific Corporation, with regard to any matters before the United States Patent and Trademark Office, any foreign patent offices, and any international patent entities, (2) to execute power of attorney documents on behalf of any of the corporations identified above, including Boston Scientific Corporation, to appoint and/or establish any attorneys, agents, and/or law firms to act on behalf of any of the corporations identified above, including Boston Scientific Corporation, in any foreign or international patent applications filed with any foreign and/or international patent offices, and (3) to execute assignment and ownership documents on behalf of any of the corporations identified above, including Boston Scientific Corporation, with regard to any matters before the United States Patent and Trademark Office, any foreign patent offices, and any international patent offices:

Victoria Aguilera Puissant	Reg. No. 56,871
Alana Bergman	Reg. No. 47,420
Laura H. Bishop	Reg. No. 47,424
Scott T. Blum	Reg. No. 40,916
James R. Chuapetta	Reg. No. 39,634
Richard R. Clapp	Reg. No. 31,751
Jeffrey P. Cook	Reg. No. 48,649
Bridget A. Cooney	Reg. No. 54,681
Luke R. Dohmen	Reg. No. 36,783
Peter J. Cafner	Reg. No. 36,517
Bryant R. Gold	Reg. No. 29,715

Lori J. Heinrichs	Reg. No. 43,667
Albert K. Kau	Reg. No. 40,672
Philip H. Lee	Reg. No. 50,645
Kurt W. Lockwood	Reg. No. 40,704
Jeffrey Z. Mann	Reg. No. 51,994
Steven A. McAuley	Reg. No. 46,084
Todd P. Messal	Reg. No. 42,883
Tyler L. Nasiedlak	Reg. No. 40,099
William J. Shaw	Reg. No. 43,111
Sarah G. Stolpman	Reg. No. 57,000



Paul W. Sandman
Executive Vice President, Secretary, and General Counsel

1/8/07
Date

COMMONWEALTH OF MASSACHUSETTS

COUNTY OF MIDDLESEX

On this 8th day of January, 2007 before me personally appeared Paul W. Sandman to me known and known to me to be the person described in and who executed the foregoing instrument, and he duly acknowledged to me that he executed the same for the uses and purposes set forth herein.


Nona E. Hurd
NOTARY PUBLIC

My commission expires Sept. 18, 2009

(s) Limited Authority (01/01/2007)

PTO/SB/98 (09-04)

Approved for use through 07/31/2008 OMB D651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Thomas J. Hiblar et alApplication No /Patent No 6,800,083 Filed/Issue Date 10/5/04Entitled: COMPRESSIBLE ATHERECTOMY BURRBOSTON SCIENTIFIC SCIMED, INC. a Corporation
(Name of Assignee) (Type of Assignee is g., corporation, partnership, university, government agency, etc.)

states that it is

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest
The extent (by percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either.

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____ Frame _____ or for which a copy thereof is attached

- OR
- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below.

1. From: Thomas J. Hiblar et al. To: SCIMED LIFE SYSTEMS, INC
The document was recorded in the United States Patent and Trademark Office at
Reel 011708 Frame 0244 or for which a copy thereof is attached
2. From: SCIMED LIFE SYSTEMS, INC To: BOSTON SCIENTIFIC SCIMED, INC
The document was recorded in the United States Patent and Trademark Office at
Reel 018505 Frame 0868 or for which a copy thereof is attached
3. From: _____ To _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____ Frame _____ or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

- ☐ Copies of assignments or other documents in the chain of title are attached.
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee

Signature

Date

Glen M. Seeger

Printed or Typed Name

612-677-9050

Telephone Number

Attorney for Applicants

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 112 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2